Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder

Viloxazine extended‐release capsules (viloxazine ER; Qelbree) is a novel nonstimulant, recently approved by the US Food and Drug Administration for the treatment of ADHD in pediatrics. Here, we characterize the pharmacokinetics (PK) of viloxazine and its major metabolite, 5‐HVLX‐gluc, using a popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Azmi, Gomeni, Roberto, Wang, Zhao, Kosheleff, Alisa R., Xie, Lanyi, Adeojo, Lilian W., Schwabe, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291887/
https://www.ncbi.nlm.nih.gov/pubmed/34269426
http://dx.doi.org/10.1002/jcph.1940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291887/
https://www.ncbi.nlm.nih.gov/pubmed/34269426
http://dx.doi.org/10.1002/jcph.1940

Ejemplares similares